ClinicalTrials.gg
Not yet recruitingNCT06994312Updated May 29, 2025

The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration

An interventional study of Nafamostat Mesylate and sodium citrate in Sepsis-induced Coagulopathy (SIC), sponsored by The First Hospital of Jilin University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by The First Hospital of Jilin University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In sepsis, the body is prone to coagulation system disorders, which may progress to sepsis-induced coagulopathy (SIC). When SIC is persistent and cannot be corrected, it often sequentially develops into disseminated intravascular coagulation (DIC) with multiple organ failure. Nafamostat mesylate can be used as an anticoagulant during blood purification in critically ill patients and is also used to treat SIC.Safe and effective anticoagulation is a prerequisite for the success of blood purification therapy. For patients with active bleeding or at risk of bleeding, how to achieve extracorporeal anticoagulation without affecting the body's coagulation function is a major clinical challenge. Nafamostat mesylate can reduce the risk of bleeding during blood purification, but its impact on the survival outcomes of patients with SIC undergoing blood purification therapy remains unclear.The aim of this study is to evaluate the impact of nafamostat mesylate treatment on the prognosis of patients with sepsis-induced coagulopathy undergoing hemofiltration.

02

Conditions studied

  • Sepsis-induced Coagulopathy (SIC)

Browse trials for

Keywords

  • Single-Center, Prospective, Randomized Controlled Trial
  • sepsis-induced coagulopathy (SIC)
  • Nafamostat Mesylate
  • Prognosis
  • Hemofiltration
03

In context

Sepsis

2,422 studies on the registry are indexed under Sepsis; 543 are open to participants now.

This study's planned enrollment of 282 is above the median of 102 across 1,167 interventional studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

The First Hospital of Jilin University is the lead sponsor of 186 studies on the registry; 97 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (Age ≥ 18 years);
  • Patients with SIC Undergoing Hemofiltration.

Exclusion criteria

Exclusion Criteria:

  • Individuals under the age of 18, pregnant women, and breastfeeding mothers;
  • Patients with a history of high sensitivity to nafamostat mesylate (those who have experienced significant bleeding complications from previous use of nafamostat mesylate);
  • Fibrinogen \< 1.5 g/L;
  • Patients with bleeding or high risk of bleeding:

Those in the acute phase of trauma or with active bleeding (e.g., flail chest, obvious contusions of the lungs, liver, spleen, retroperitoneal bleeding, pelvic fractures, etc.); Those with a history of severe head trauma, intracranial surgery, stroke, cerebral aneurysm, or arteriovenous malformation within one month prior to enrollment; Those with a history of congenital bleeding disorders: such as hemophilia; Those with underlying fulminant hepatitis, decompensated cirrhosis, or other severe liver diseases.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
282 participants (estimated)

Study arms

  • Experimental
    Nafamostat Mesylate Group

    Nafamostat mesylate (50 mg/vial, Jiangsu DuRui Pharmaceutical Co., Ltd.) is dissolved and prepared with 5% glucose injection solution. It is continuously infused through the anticoagulant injection tube at the start of hemofiltration, with an initial dose generally ranging from 20 to 50 mg/h. Monitoring is performed before treatment and within 2 to 4 hours after the start of treatment. In cases of active bleeding, moderate to high bleeding risk, hypercoagulable state, or high-dose use of nafamostat mesylate (NM), the monitoring frequency should be increased (e.g., every 4 to 6 hours). After the treatment becomes stable, the monitoring interval can be extended to 12 to 24 hours. The activated clotting time (ACT) or activated partial thromboplastin time (APTT) at the post-dialyzer or venous end should be maintained at 1.5 to 2.5 times the pre-treatment level, or the ACT should be maintained between 150 and 250 seconds, and the APTT between 50 and 70 seconds.

    Drug: Nafamostat Mesylate

  • Active comparator
    Sodium Citrate Group

    Patients were continuously infused with sodium citrate (200 ml/bag, Chengdu Qingshanlikang Pharmaceutical Co., Ltd.). The initial pump rate of 4% sodium citrate was set at 2.1% of the blood flow rate, and the initial pump rate of 10% calcium gluconate was set at 7.3% of the flow rate of 4% sodium citrate. Adjust the doses of sodium citrate and calcium gluconate based on the levels of ionized calcium in arterial and venous blood gases.The goal is to maintain arterial blood ionized calcium levels at 1.00-1.20 mmol/L and venous blood ionized calcium levels at 0.21-0.40 mmol/L.

    Drug: sodium citrate

Interventions

  • DrugNafamostatStudies of NafamostatNafamostat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Anticoagulation with Nafamostat Mesylate for SIC Patients Undergoing Hemofiltration

    Also known as: Experimental Group

  • Anticoagulation with Sodium Citrate for SIC Patients Undergoing Hemofiltration

    Also known as: Control Group

06

What researchers measure

Primary outcomes

  1. ICU Mortality Rates

    The proportion of patients who died during the ICU stay out of the total number of patients in the group.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Average Filter Lifespan

    The total sum of all filter usage times for each patient divided by the number of filters used.

    Time frame: Through study completion, an average of 1 year

  2. ICU length of stay

    Length of Stay in the ICU

    Time frame: Through study completion, an average of 1 year

  3. 28-day mortality

    The proportion of patients who died within 28 days out of the total number of patients in the group.

    Time frame: Through study completion, an average of 1 year

  4. Incidence of Bleeding

    The proportion of patients experiencing bleeding events (such as cerebral hemorrhage, gastrointestinal bleeding, etc.) during the ICU stay out of the total number of patients.

    Time frame: Through study completion, an average of 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for May 2028, 34 months later.

Of 302 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 34 months is above that.

Counting every sponsor, half of 325 studies reached it within 22 months; a quarter within 11 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
May 29, 2025
StartEst.
Jul 1, 2025
Primary completionEst.
May 1, 2028
CompletionEst.
Dec 1, 2028
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06994312
Responsible party
Sponsor
First posted
May 29, 2025
Start date
Jul 1, 2025 (estimated)
Primary completion
May 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
May 29, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nafamostat

Start the discussion